SAITO RYOTA

Research theme for competitive and other funds (1)：

2022 - 2025 Keap1-Nrf2システムに着目した慢性閉塞性肺疾患の発症メカニズムの解明

Papers (25)：

Nozomu Kimura, Yoko Tsukita, Risa Ebina-Shibuya, Eisaku Miyauchi, Mitsuhiro Yamada, Daisuke Narita, Ryota Saito, Chihiro Inoue, Naoya Fujino, Tomohiro Ichikawa, et al. Peripheral blood biomarkers associated with combination of immune checkpoint blockade plus chemotherapy in NSCLC. Cancer biomarkers : section A of Disease markers. 2024
Kana Watanabe, Ryota Saito, Eisaku Miyauchi, Hiromi Nagashima, Atsushi Nakamura, Shunichi Sugawara, Nobuyuki Tanaka, Hiroshi Terasaki, Tatsuro Fukuhara, Makoto Maemondo. Monitoring of Plasma EGFR Mutations during Osimertinib Treatment for NSCLC Patients with Acquired T790M Mutation. Cancers. 2023. 15. 17
Minehiko Inomata, Yosuke Kawashima, Ryota Saito, Daisuke Morinaga, Hitomi Nogawa, Masamichi Sato, Yohei Suzuki, Satoru Yanagisawa, Takashi Kikuchi, Daisuke Jingu, et al. A retrospective study of the efficacy of combined EGFR-TKI plus VEGF inhibitor/cytotoxic therapy vs. EGFR-TKI monotherapy for PD-L1-positive EGFR-mutant non-small cell lung cancer: North Japan Lung Cancer Study Group 2202. Oncology letters. 2023. 26. 2. 334-334
木村望, 突田容子, 渋谷里紗, 宮内栄作, 角藤翔, 成田大輔, 斎藤良太, 杉浦久敏. 肺癌効果予測因子非小細胞肺癌に対する殺細胞性抗癌剤・免疫チェックポイント阻害薬併用療法の効果予測因子の探索. 日本呼吸器学会誌. 2023. 12. 増刊. 194-194
Shinya Uematsu, Satoru Kitazono, Hisashi Tanaka, Ryota Saito, Yosuke Kawashima, Fumiyoshi Ohyanagi, Takehiro Tozuka, Tsugitomi Ryosuke, Toshio Sakatani, Atsushi Horiike, et al. Clinical efficacy of amrubicin in patients with small cell lung cancer relapse after first-line treatment including immune checkpoint inhibitors: A retrospective multicenter study (TOPGAN 2021-01). Thoracic cancer. 2022. 14. 2. 168-176

ｍore...

MISC (10)：

突田容子, 宮内栄作, 斎藤良太, 佐藤輝幸, 山本貴也, 片桐佑, 井上彰, 一ノ瀬正和. 強度変調放射線治療による根治的化学放射線療法後のデュルバルマブ使用経験の報告. 肺癌. 2019. 59. 6. 674-674
Atsushi Nakamura, Akira Inoue, Makoto Maemondo, Yoshiaki Mori, Satoshi Oizumi, Masao Harada, Shingo Takanashi, Naoto Morikawa, Takashi Ishida, Ichiro Kinoshita, et al. Randomized phase 2 trial comparing amrubicin (A) with re-challenge of platinum doublet (P) in patients (pts) with sensitive-relapsed small-cell lung cancer (SCLC). JOURNAL OF CLINICAL ONCOLOGY. 2014. 32. 15
Ryota Saito, Akira Inoue, Shunichi Sugawara, Satoshi Oizumi, Makoto Maemondo, Koichi Okudera, Toshiro Suzuki, Kazuhiro Usui, Masao Harada, Naoto Morikawa, et al. Phase II study of amrubicin (AMR) combined with carboplatin (CBDCA) for refractory relapsed small cell lung cancer (SCLC): North Japan Lung Cancer Group 0802. JOURNAL OF CLINICAL ONCOLOGY. 2012. 30. 15
Keita Kudo, Makoto Nishio, Kazuko Sakai, Azusa Tanimoto, Toshio Sakatani, Ryota Saito, Kyohei Kaburaki, Noriko Yanagitani, Atsushi Horiike, Fumiyoshi Ohyanagi, et al. Detection of EML4-ALK in serum RNA from lung cancer patients using MassARRAY platform. JOURNAL OF CLINICAL ONCOLOGY. 2012. 30. 15
Noriko Yanagitani, Toshio Sakatani, Ryota Saito, Hisashi Tanaka, Kyohei Kaburaki, Keita Kudo, Atsushi Horiike, Fumiyoshi Ohyanagi, Sachiko Hagiwara, Takeshi Horai, et al. IMPACT OF THE 7TH EDITION OF TNM CLASSIFICATION (UICC7) IN NON-SURGICAL CASES OF ADVANCED NON-SMALL CELL LUNG CANCER. JOURNAL OF THORACIC ONCOLOGY. 2011. 6. 6. S1167-S1168

ｍore...

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page